Atlas Trials

Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients

Clinical trial NCT01915576 · COMPLETED

Trial details

NCT number
NCT01915576
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Neoplasms
Start date
2013-09-01
Primary completion
2016-07-01
Enrollment
79

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.